Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Neuropharmacology ; 128: 474-481, 2018 Jan.
Article in English | MEDLINE | ID: mdl-28802645

ABSTRACT

The purinergic system consists of two large receptor families - P2X and P2Y. Both are activated by adenosine triphosphate (ATP), although presenting different functions. These receptors are present in several brain regions, including those involved in emotion and stress-related behaviors. Hence, they seem to participate in fear- and anxiety-related responses. However, few studies have investigated the purinergic system in threatening situations, as observed in contextual fear conditioning (CFC). Therefore, this study investigated the involvement of purinergic receptors in the expression and extinction of aversive memories. C57Bl/6 background mice were submitted to the CFC protocol. Wildtype (WT) mice received i.p. injection of either a nonselective P2 receptor (P2R) antagonist, P178 (10 or 30 mg/kg); a selective P2X7 receptor (P2X7R) antagonist, A438079 (10 mg/kg); a selective P2Y1 receptor (P2Y1R) antagonist, MRS2179 (10 mg/kg); or vehicle 10 min prior to or immediately after the extinction session. Additionally, P2X7R KO mice were tested in the CFC protocol. After P2R antagonist treatment, contextual fear recall increased, while acquisition of extinction was impaired. Similar results were observed with the selective P2X7R antagonist, but not with the selective P2Y1R antagonist. Interestingly, P2X7R KO mice showed increased contextual fear recall, associated with impaired acquisition of extinction, in accordance with pharmacologic P2X7R antagonism. Our results suggest that specific pharmacological or genetic blockade of P2X7R promotes anxiogenic-like effects, along with deficits in extinction learning. Thus, these receptors could present an alternative treatment of stress-related psychiatric disorders.


Subject(s)
Conditioning, Psychological/physiology , Fear/physiology , Memory/physiology , Receptors, Purinergic P2X7/metabolism , Analysis of Variance , Animals , Conditioning, Psychological/drug effects , Extinction, Psychological/drug effects , Extinction, Psychological/physiology , Fear/drug effects , Male , Memory/drug effects , Mice , Mice, Inbred C57BL , Mice, Knockout , Purinergic Agonists/pharmacology , Purinergic P2X Receptor Antagonists/pharmacology , Pyridoxal/pharmacology , Receptors, Purinergic P2X7/genetics
2.
Sci Rep ; 7(1): 14094, 2017 10 26.
Article in English | MEDLINE | ID: mdl-29074877

ABSTRACT

Exposure to loud sounds has become increasingly common. The most common consequences of loud sound exposure are deafness and tinnitus, but emotional and cognitive problems are also associated with loud sound exposure. Loud sounds can activate the hipothalamic-pituitary-adrenal axis resulting in the secretion of corticosterone, which affects hippocampal synaptic plasticity. Previously we have shown that long-term exposure to short episodes of high intensity sound inhibited hippocampal long-term potentiation (LTP) without affecting spatial learning and memory. Here we aimed to study the impact of short term loud sound exposure on hippocampal synaptic plasticity and function. We found that a single minute of 110 dB sound inhibits hippocampal Schaffer-CA1 LTP for 24 hours. This effect did not occur with an 80-dB sound exposure, was not correlated with corticosterone secretion and was also observed in the perforant-dentate gyrus synapse. We found that despite the deficit in the LTP these animals presented normal spatial learning and memory and fear conditioning. We conclude that a single episode of high-intensity sound impairs hippocampal LTP, without impairing memory and learning. Our results show that the hippocampus is very responsive to loud sounds which can have a potential, but not yet identified, impact on its function.


Subject(s)
Auditory Perception/physiology , Hippocampus/physiology , Long-Term Potentiation/physiology , Acoustic Stimulation , Action Potentials/physiology , Animals , Conditioning, Psychological/physiology , Corticosterone/metabolism , Excitatory Postsynaptic Potentials , Fear/physiology , Male , Rats, Wistar , Spatial Learning/physiology , Spatial Memory/physiology , Spatial Navigation/physiology , Synapses/physiology , Tissue Culture Techniques
3.
Vitam Horm ; 103: 193-279, 2017.
Article in English | MEDLINE | ID: mdl-28061971

ABSTRACT

The medical properties of Cannabis sativa is known for centuries. Since the discovery and characterization of the endogenous cannabinoid system, several studies have evaluated how cannabinoid compounds and, particularly, how the modulation of the endocannabinoid (eCB) system influences a wide range of functions, from metabolic to mental disorders. Cannabinoids and eCB system often exert opposite effects on several functions, such as anxiety. Although the mechanisms are not completely understood, evidence points to different factors influencing those effects. In this chapter, the recent advances in research about the relationship between eCB system and anxiety disorders in humans, as well as in animal models, will be discussed. The recent data addressing modulation of the eCBs in specific brain areas, such as the medial prefrontal cortex, amygdaloid complex, bed nucleus of stria terminalis, hippocampus, and dorsal periaqueductal gray, will be summarized. Finally, data from animal models addressing the mechanisms through which the eCB system modulates anxiety-related behavior dependent on stressful situations, such as the involvement of different receptors, distinct eCBs, modulation of neurotransmitters release, HPA axis and immune system activation, and plastic mechanisms, will also be discussed.


Subject(s)
Anxiety Disorders/metabolism , Anxiety/metabolism , Brain/metabolism , Endocannabinoids/metabolism , Neurons/metabolism , Neuroprotection , Receptors, Cannabinoid/metabolism , Animals , Anxiety/genetics , Anxiety/immunology , Anxiety Disorders/genetics , Anxiety Disorders/immunology , Brain/immunology , Endocannabinoids/immunology , Fear , Genetic Predisposition to Disease , Humans , Hypothalamo-Hypophyseal System/immunology , Hypothalamo-Hypophyseal System/metabolism , Nerve Tissue Proteins/agonists , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Neuronal Plasticity , Neurons/immunology , Organ Specificity , Pituitary-Adrenal System/immunology , Pituitary-Adrenal System/metabolism , Polymorphism, Single Nucleotide , Receptors, Cannabinoid/chemistry , Receptors, Cannabinoid/genetics
4.
Neurosci Biobehav Rev ; 46 Pt 3: 418-28, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24726577

ABSTRACT

The Transient Receptor Potential Vanilloid Type-1 (TRPV1) was first characterized in primary afferent fibers as a receptor for capsaicin (the pungent ingredient of chili peppers). Later on, this cation-permeable ion channel was also described in the central nervous system, where its main putative endogenous ligand is N-arachidonoyl ethanolamide (an endocannabinoid, also known as anandamide). Recent results employing genetic, pharmacological and histochemical techniques indicate that TRPV1 tonically modulate anxiety, fear and panic responses in brain regions related to defensive responses, such as the dorsal periaqueductal gray, the hippocampus and the medial prefrontal cortex. Genetic deletion or antagonism of this ion channel induces anxiolytic-like effects in several animal models. The main mechanism responsible for TRPV1-mediated effects on anxiety seems to involve facilitation of glutamatergic neurotransmission. In addition, there is evidence for interactions with other neurotransmitter systems, such as nitric oxide and endocannabinoids.


Subject(s)
Brain/metabolism , Defense Mechanisms , TRPV Cation Channels/physiology , Animals , Anxiety/drug therapy , Anxiety/pathology , Disease Models, Animal , Humans , Models, Biological
5.
Neuroscience ; 204: 186-92, 2012 Mar 01.
Article in English | MEDLINE | ID: mdl-21906661

ABSTRACT

The transient receptor potential vanilloid type 1 channel (TRPV1; originally vanilloid receptor VR1) is activated in peripheral terminals of nociceptive fibers by noxious heat, low pH, and natural products such as capsaicin, the pungent ingredient of red-hot chilli peppers. Evidence has been accumulating that TRPV1 is expressed also in the brain, where it seems to be involved in antinociception, locomotor control, and regulation of affective behaviors. This ion channel might be activated by arachidonoyl ethanolamide (anandamide), the endogenous agonist of the cannabinoid type 1 (CB(1)) receptor. However, while CB(1) activation leads to a decrease in intracellular calcium and attenuation of synaptic transmission, anandamide binding to TRPV1 results in elevated calcium levels and potentiated synaptic transmission. This suggests a tripartite regulatory system with antagonistic effects of CB(1) and TRPV1, which are tied together by the same endogenous ligand. Such a system may have important implication for the modulation of behavioral responses. The present commentary elaborates on this interplay between CB(1) receptors and TRPV1 channels in the context of fear- and anxiety-related behaviors.


Subject(s)
Anxiety/metabolism , Fear/physiology , Receptor, Cannabinoid, CB1/metabolism , TRPV Cation Channels/metabolism , Animals , Signal Transduction/physiology , Stress, Psychological/metabolism
6.
Neural Plast ; 2009: 625469, 2009.
Article in English | MEDLINE | ID: mdl-19096514

ABSTRACT

Cannabinoids play an important role in activity-dependent changes in synaptic activity and can interfere in several brain functions, including responses to aversive stimuli. The regions responsible for their effects, however, are still unclear. Cannabinoid type 1 (CB1) receptors are widely distributed in the central nervous system and are present in the periaqueductal gray (PAG), a midbrain structure closely involved in responses related to aversive states. Accordingly, exposure to stressful stimuli increases endocannabinoid (eCB) levels in the PAG, and local administration of CB1 agonists or drugs that facilitate eCB-mediated neurotransmission produces antinociceptive and antiaversive effects. To investigate if these drugs would also interfere in animal models that are sensitive to anxiolytic drugs, we verified the responses to intra-PAG injection of CB1 agonists in rats submitted to the elevated plus-maze, the Vogel punished licking test, or contextual aversive conditioning model. The drugs induced anxiolytic-like effects in all tests. The same was observed with the transient receptor potential vanilloid type 1 (TRPV1) antagonist capsazepine and with cannabidiol, a nonpsychotomimetic phytocannabinoid that produces anxiolytic-like effects after systemic administration in humans and laboratory animals. These results, therefore, suggest that the PAG could be an important site for the antiaversive effects of cannabinoids.


Subject(s)
Cannabinoids/pharmacology , Periaqueductal Gray/drug effects , Periaqueductal Gray/physiology , Animals , Anti-Anxiety Agents/pharmacology , Cannabidiol/pharmacology , Capsaicin/analogs & derivatives , Capsaicin/pharmacology , Microinjections , Rats , Receptor, Cannabinoid, CB1/agonists , Stress, Physiological/drug effects , Synaptic Transmission/physiology , TRPV Cation Channels/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL
...